State of Wyoming Increases Holdings in Eli Lilly and Company (NYSE:LLY)

State of Wyoming grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 92.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,552 shares of the company's stock after acquiring an additional 747 shares during the period. State of Wyoming's holdings in Eli Lilly and Company were worth $1,198,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in LLY. Grassi Investment Management lifted its position in shares of Eli Lilly and Company by 0.3% in the fourth quarter. Grassi Investment Management now owns 79,512 shares of the company's stock worth $61,383,000 after buying an additional 225 shares in the last quarter. Elevate Capital Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $262,000. Inspirion Wealth Advisors LLC lifted its position in shares of Eli Lilly and Company by 4.0% in the fourth quarter. Inspirion Wealth Advisors LLC now owns 623 shares of the company's stock worth $482,000 after buying an additional 24 shares in the last quarter. Carnegie Investment Counsel lifted its position in shares of Eli Lilly and Company by 16.4% in the fourth quarter. Carnegie Investment Counsel now owns 8,462 shares of the company's stock worth $6,533,000 after buying an additional 1,194 shares in the last quarter. Finally, JGP Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 2.6% in the fourth quarter. JGP Wealth Management LLC now owns 1,798 shares of the company's stock worth $1,388,000 after buying an additional 46 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Trading Up 3.3%

LLY opened at $757.23 on Friday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market cap of $717.65 billion, a price-to-earnings ratio of 64.67, a P/E/G ratio of 1.40 and a beta of 0.48. The stock's 50 day moving average price is $797.84 and its 200-day moving average price is $805.85. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.58 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.79%. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Analyst Ratings Changes

A number of research firms recently commented on LLY. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Truist Financial boosted their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Finally, Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.